<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Clinical manifestations and treatment of syphilis in nonpregnant adults</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Clinical manifestations and treatment of syphilis in nonpregnant adults</h1>
<div class="graphic"><div class="figure"><div class="ttl">Clinical manifestations and treatment of syphilis in nonpregnant adults</div><div class="cntnt"><table cellspacing="0"><colgroup width="13%"></colgroup> <colgroup span="3" width="29%"></colgroup> <tbody> <tr> <td class="subtitle1"> </td> <td class="subtitle1">Clinical <span class="nowrap_whitespace">manifestations<sup>*</sup></span></td> <td class="subtitle1"><span class="nowrap_whitespace">Treatment<sup>¶</sup></span></td> <td class="subtitle1">Monitoring after <span class="nowrap_whitespace">treatment<sup>Δ</sup></span></td> </tr> <tr> <td><strong>Early syphilis</strong></td> <td> <p><strong>Primary syphilis:</strong><br/> Typically consists of a single painless chancre at the site of inoculation, accompanied by regional adenopathy.</p> <p><strong>Secondary syphilis:</strong><br/> A systemic illness that often includes a rash (disseminated and/or involving the palms and soles), fever, malaise, and other symptoms such as pharyngitis, hepatitis, mucous patches, condyloma lata, alopecia.</p> <strong>Early latent:</strong><br/> Refers to the period when a patient is infected with <em>Treponema pallidum</em> as demonstrated by serologic testing but has no symptoms. Early latent syphilis occurs within the first year of initial infection.</td> <td><strong>Preferred:</strong> <ul class="decimal_heading"> <li>Penicillin G benzathine 2.4 million units IM once</li> </ul> <p class="extra_spacing_top"><strong>Alternatives (choose</strong> <span class="nowrap_whitespace"><strong>one):</strong><sup>◊</sup></span></p> <ul class="decimal_heading"> <li>Doxycycline 100 mg orally twice daily for 14 <span class="nowrap_whitespace">days<sup>§</sup></span></li> <li>Ceftriaxone 1 g daily IM or IV for 10 to 14 days</li> </ul> </td> <td> <p>Clinical exam and serologic testing with a nontreponemal test (eg, RPR) at 6 and 12 months.</p> Titers should be checked more frequently if the patient is HIV infected, follow-up is uncertain, or reinfection is a concern.</td> </tr> <tr> <td><strong>Late syphilis</strong></td> <td> <p><strong>Tertiary syphilis:</strong><br/> Patients with late syphilis who have symptomatic manifestations involving the cardiovascular system or gummatous disease (granulomatous disease of the skin and subcutaneous tissues, bones, or viscera).</p> <strong>Late latent syphilis:</strong><br/> The period when a patient is infected with <em>T. pallidum</em> as demonstrated by serologic testing but has no symptoms. Late latent syphilis by definition is present more than one year after initial infection. If the timing of an infection is not known, late latent syphilis is presumed.</td> <td><strong>Preferred:</strong> <ul class="decimal_heading"> <li>Penicillin G benzathine 2.4 million units IM once weekly for three weeks</li> </ul> <p class="extra_spacing_top"><strong>Alternatives (choose one):</strong></p> <ul class="decimal_heading"> <li>Doxycycline 100 mg orally twice daily for four <span class="nowrap_whitespace">weeks<sup>§</sup></span></li> <li>Ceftriaxone 2 g daily IM or IV for 10 to 14 days</li> </ul> </td> <td>Clinical exam and serologic testing with a nontreponemal test (eg, RPR) at 6, 12, and 24 months.</td> </tr> <tr> <td><strong>Neurosyphilis</strong></td> <td> <p><strong>Neurosyphilis:</strong><br/> Can occur at any time during the course of infection.</p> <p><strong>Early neurosyphilis:</strong><br/> Patients with early neurosyphilis may have asymptomatic meningitis, symptomatic meningitis, or less commonly meningovascular disease (ie, meningitis or stroke). Vision or hearing loss with or without concomitant meningitis may also be present, and ocular/otologic syphilis is treated as neurosyphilis.</p> <strong>Late neurosyphilis:</strong><br/> The most common forms involve the brain and spinal cord (dementia [general paresis] and tabes dorsalis).</td> <td><strong>Preferred:</strong> <ul class="decimal_heading"> <li>Aqueous penicillin G 3 to 4 million units IV every four hours (or 18 to 24 million units continuous IV infusion) for 10 to 14 days</li> <li>For patients with late neurosyphilis, some experts give an additional dose of penicillin G benzathine (2.4 million units IM once) after completing IV <span class="nowrap_whitespace">therapy.<sup>¥</sup></span></li> <li>If possible, patients allergic to penicillin should be desensitized and treated with IV penicillin</li> </ul> <p class="extra_spacing_top"><span class="nowrap_whitespace"><strong>Alternative:</strong><sup>‡</sup></span></p> <ul class="decimal_heading"> <li>Ceftriaxone 2 g IV daily for 10 to 14 days</li> </ul> </td> <td> <p>Clinical and serologic monitoring with nontreponemal tests (eg, RPR). The frequency depends upon the stage of disease (eg, early or late).</p> CSF monitoring may be <span class="nowrap_whitespace">warranted.<sup>†</sup></span></td> </tr> </tbody></table></div><div class="graphic_footnotes"><p>CSF: cerebrospinal fluid;
    IM: intramuscular;
    IV: intravenous;
    RPR: rapid plasma reagin.</p>
<p>* Refer to the topics that discuss the clinical manifestations of syphilis and neurosyphilis for more detailed information.</p>
<p>¶ For the treatment of pregnant women and children, refer to the topics that discuss syphilis and pregnancy and congenital syphilis.</p>
<p>Δ Patients infected with HIV are typically monitored more frequently. Refer to the topic that discusses the treatment of syphilis in patients with HIV infection.</p>
<p>◊ Amoxicillin 3 g plus probenecid 500 mg, both given orally twice daily for 14 days, is another alternative but is rarely used given the complexity of the regimen. A single dose of azithromycin 2 g administered orally is also an alternative but only if other options are not possible since azithromycin resistance is a concern.</p>
<p>§ Tetracycline 500 mg orally four times daily is also an alternative but is harder to take.</p>
<p>¥ For patients with clinical manifestations of late neurosyphilis (eg, general paresis or tabes dorsalis), we suggest an additional single dose of IM penicillin G benzathine after the IV course. Without this IM dose, the duration of treatment for neurosyphilis is shorter than the regimens used for other forms of late
    syphilis and may be insufficient. However, data supporting this approach are lacking, and it is reasonable for a patient or provider to defer this additional dose.</p>
<p>‡ Limited clinical experience suggests that doxycycline (200 mg orally twice daily) for 21 to 28 days may be effective as an alternative regimen. However, this regimen should be reserved for exceptional circumstances.</p>
    
    † Refer to the topic on neurosyphilis for a more detailed discussion of monitoring after treatment.</div><div id="graphicVersion">Graphic 50435 Version 12.0</div></div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
